TRVITrevi Therapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Trevi Therapeutics, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRVIThis | $2.2B#8 | — | 6.7x#9 | — | — | 10.7%#7 | — | -13.3%#4 | — | — | 91.0%#3 | — |
| NKTR | $2.3B#1 | — | 2.6x#4 | 42.4x#8 | -43.9%#11 | -37.8%#10 | -253.7%#7 | -18.2%#5 | -14.0%#3 | — | 34.1%#8 | — |
| SLS | $2.3B#2 | — | 16.8x#13 | — | -100.0%#12 | 13.0%#5 | — | -19.5%#7 | — | — | 574.9%#1 | — |
| OCUL | $2.3B#3 | — | 4.4x#5 | 43.8x#9 | -18.5%#10 | -37.4%#9 | -519.8%#9 | -51.1%#11 | — | — | -14.7%#14 | — |
| PVLA | $2.2B#4 | — | 10.3x#12 | 52.3x#10 | 65.3%#4 | -139.3%#12 | -90.2%#6 | -19.2%#6 | — | — | 174.6%#2 | — |
| GENB | $2.2B#5 | — | 4.9x#7 | — | — | — | — | 0.0%#2 | — | — | — | — |
| PBH | $2.2B#6 | 12.9x#1 | 1.1x#1 | 2.0x#3 | -4.3%#9 | -11.3%#8 | 28.4%#1 | 9.9%#1 | 5.9%#1 | 4#1 | -27.8%#15 | — |
| SRPT | $2.2B#7 | — | 1.4x#2 | 1.2x#2 | 4.3%#8 | -403.3%#15 | -37.5%#4 | -46.7%#10 | -73.0%#4 | — | 20.8%#10 | — |
| ZBIO | $2.2B#9 | — | 8.7x#11 | 215.1x#11 | 100.0%#3 | -140.6%#13 | -3830.6%#11 | -152.9%#14 | -296.6%#6 | — | 72.7%#6 | — |
| NUVB | $2.1B#10 | — | 8.5x#10 | 34.1x#6 | 699.0%#1 | 64.0%#3 | -338.7%#8 | -80.6%#12 | -87.4%#5 | — | 86.3%#4 | — |
| BHC | $2.1B#11 | — | — | 0.2x#1 | 6.7%#7 | 441.3%#1 | 17.7%#2 | — | 3.6%#2 | — | -2.1%#11 | 16.6%#1 |
| AGIO | $2.0B#12 | — | 2.0x#3 | 37.9x#7 | 48.0%#5 | -161.3%#14 | -873.9%#10 | -40.3%#9 | — | — | -5.8%#12 | — |
| RAPP | $2.0B#14 | — | 4.7x#6 | — | — | -42.4%#11 | — | -26.4%#8 | — | — | 59.2%#7 | — |
| BHVN | $2.0B#13 | — | 164.6x#15 | — | — | 12.7%#6 | — | -6045.0%#15 | — | — | -9.5%#13 | — |
| ZYME | $2.0B#15 | — | 24.4x#14 | 18.5x#5 | 38.9%#6 | 33.9%#4 | -87.3%#5 | -100.9%#13 | — | — | 73.9%#5 | — |
| STOK | $1.9B#16 | — | 5.4x#8 | 10.2x#4 | 404.5%#2 | 92.3%#2 | -11.2%#3 | -2.0%#3 | — | — | 27.6%#9 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice